Implementation of New Imaging Techniques, Biomarkers and New Treatments in Prostate Cancer

Guest Editors:

Dr. Felipe Couñago
Radiation Oncologist, National Clinical Director GenesisCare Spain, Vithas La Milagrosa and San Francisco de Asis Hospitals, 28002 Madrid, Spain

Dr. Thomas Zilli
Dept Radiat Oncol, University of Geneva, Geneva, Switzerland

Dr. Fernando López Campos
Dept Radiat Oncol, Hospital Universitario Ramon y Cajal, Madrid, Spain

Deadline for manuscript submissions:
closed (31 October 2022)

Message from the Guest Editors

We are living in an era of unprecedented development in prostate cancer, both in the diagnosis of the disease with the introduction of multiparametric magnetic resonance imaging and positron emission tomography (PET) with new radiotracers (PSMA, fluciclovine, etc.), as well as with the implementation of molecular biomarkers (serum and urinary markers, genomic classifiers, genes associated with alterations in DNA repair, mismatch repair, etc.) which have diagnostic and prognostic implications that can allow us to personalize the treatment for our patients.

The number of therapeutic options for castration-resistant and metastatic prostate cancer has substantially increased over the last few years. The traditional treatment for these patients (i.e., androgen deprivation therapy) is now considered suboptimal. Moreover, in patients with oligometastatic disease or low tumor burden, metastasis-directed therapy combined with systemic treatments is another area of growing interest.

This Special Issue aims to explore the technological and therapeutic advances that already have a clinical use or that can transform the diagnostic and treatment paths of prostate cancer in the coming years.

mdpi.com/si/101911

Special Issue

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us